March 25th 2024
A new study finds that the use of continuous glucose monitoring helps reduce complications from type 1 diabetes, lowering the risk of developing or progressing diabetic retinopathy.
Some Mental Health Conditions Add to the Atrial Fibrillation Risk from Diabetes, Study Finds
December 9th 2022Korean study shows that depression, insomnia and anxiety add to the risk of atrial fibrillation among those with diabetes, according to a Korean study. Those mental health condition may affect the autonomic nervous system that regulates the heart. Bipolar disorder and schizophrenia did not increase the risk.
Read More
Dialing Up Telehealth to Comprehensive Level Makes it More Effective: JAMA Internal Medicine Study
July 28th 2022Results reported this week in JAMA Internal Medicine show a steeper decrease in HbA1C among people with poorly controlled type 2 diabetes who participated in a telehealth program that included telemonitoring, self-management support, medication management and services for depression. The comprehensive program cost about $1,500 more per year than the control program of standard telemonitoring and care coordination.
Read More
Type 2 Diabetes: Considerations for Achieving Targeted Glycemic Control
January 20th 2022Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.
Watch
FDA Updates: Merck’s Pneumococcal Vaccine Leads the Week
July 24th 2021New vaccine for pneumococcal disease, an sNDA approved based on real-world data, a new therapy for skin and muscle disease, Keytruda combination receives full approval in endometrial cancer, a new diabetes therapy is approved, and another JAK inhibitor misses PDUFA date round out this week’s FDA news.
Read More
FDA Update: Keytruda and Aduhelm News Leads the Week
July 10th 2021Keytruda loses one indication but gains another, Biogen narrows use of Aduhelm, Padcev gets regular approval and expanded indication, Amgen submits application for asthma biologic, agency issues complete response letter for diabetes prevention therapy teplizumab, Novartis resubmits NDA for inclisiran.
Read More
Today’s Effects of Telehealth When Caring for Diabetic Children
April 23rd 2021Dr. Kathleen Bethin, clinical professor, and Dr. Lucy Mastrandrea, associate professor and division chief of endocrinology/diabetes both at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo, spoke with Vic Baldry of Cecelia Health to discuss the challenges telehealth has created when caring for families with children who have type 1 diabetes.
Read More
SGLT2 Inhibitor Use Stunted for Black, Female, Lower Income Type 2 Diabetes Patients
April 21st 2021Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.
Read More
Flu Shots Are More Important Than Ever for People with Diabetes, ASCVD
October 14th 2020Flu increases the risk of heart attack, especially among people with diabetes and atherosclerotic cardiovascular disease (ASCVD). COVID-19 and the possibility of co-infection makes getting vaccinated against the flu particularly important this year.
Read More
Anti-VEGF Therapy for Diabetic Retinopathy Gets to the Root Cause
September 14th 2020Drugs block the formation of tiny blood vessels in the retina that are prone to breaking open, resulting in bleeds that can cause serious vision impairment and blindness, explains ADA chief scientific and medical officer, Robert Gabbay, in this conclusion of a four-part video series.
Watch